Low-dose naltrexone as treatment for epidermolysis bullosa pruriginosa-associated refractory pruritus

Case Reports; JAAD Case Rep
19 June 2023
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339115/

Low-Dose Naltrexone in Rheumatological Diseases

Mediterr J Rheumatol
31 March 2023
https://pubmed.ncbi.nlm.nih.gov/37223594/

Background: Naltrexone has been approved for alcohol and opioid abuse by the FDA. At low-dose naltrexone (LDN) has been used in several diseases including chronic pain and autoimmune conditions, including rheumatic disorders.

The LDN 3: To Purchase with discounts before 1st September 2022 Go to ldnresearchtrust.org/ldn-book-3 for full details

LDN Webinar 18 May 2022 (LDN; low dose naltrexone)

LDN Questions Answered Live by

Pharmacist Dr Masoud Rashidi - LDN Specialist
Dr Sato-Re
Dr Mathewson

Sponsored by Innovative Compounding Pharmacy icpfolsom.com